AgomAb Therapeutics (NASDAQ:AGMB) Director David Epstein Purchases 15,000 Shares of Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein acquired 15,000 shares of the company’s stock in a transaction dated Thursday, November 5th. The shares were bought at an average cost of $6.90 per share, with a total value of $103,500.00. Following the purchase, the director owned 40,000 shares in the company, valued at approximately $276,000. The trade was a 60.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

AgomAb Therapeutics Trading Up 9.6%

Shares of AGMB stock traded up $0.67 during trading hours on Friday, hitting $7.64. 158,411 shares of the company were exchanged, compared to its average volume of 114,936. The firm has a fifty day moving average of $10.26 and a 200 day moving average of $11.86. AgomAb Therapeutics NV has a 1 year low of $6.46 and a 1 year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last released its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that AgomAb Therapeutics NV will post -1.77 EPS for the current year.

Analyst Upgrades and Downgrades

AGMB has been the subject of several research reports. Wall Street Zen cut shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, October 21st. Piper Sandler assumed coverage on AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price on the stock. B. Riley Financial started coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They set a “buy” rating and a $34.00 price target for the company. Finally, Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a research note on Wednesday, August 19th. They set an “overweight” rating for the company. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company focused on developing medicines that promote tissue regeneration and address diseases associated with fibrosis and tissue damage. The company’s research is centered on biological pathways involved in repair, remodeling and the disease microenvironment.

Agomab’s lead program is AGMB-129, an orally administered, gut-restricted small-molecule inhibitor of transforming growth factor beta receptor 1, also known as ALK5. The program is being developed for intestinal fibrosis associated with Crohn’s disease, a condition in which scar tissue can narrow the intestine and contribute to complications.

The company also maintains earlier-stage discovery and development programs intended to apply its regenerative medicine expertise to additional gastrointestinal and oncology-related indications.